– The vaccine maker saw its shares fall 4.3% after the company said it expects to report data from its Covid-19 vaccine trials involving 2- to 5-year-olds by March. The company could file for approval to vaccinate that age group if the data is supportive, it said in a statement.
Corporate profits are breaking records, what with their “inflation”
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação: